Wohl & Fruchter LLP

Call Us 866-833-6245

  • About
  • Attorneys
  • Practice Areas
  • Cases
  • Results
  • News
  • Contact
  1. Home
  2. Cases
  3. CDK Global

CDK Global

We are investigating whether the directors of CDK Global, Inc. (ticker: CDK) (“CDK”) acted in the best interests of CDK shareholders in approving the sale of CDK to Brookfield Business Partners (“Brookfield”) for $54.87 per share in cash in a tender offer.

If you remain a CDK shareholder and have questions about your legal rights, please contact our firm via the form below to discuss your options at no charge.

Why is there an investigation?
On April 7, 2022, CDK announced an agreement for Brookfield to purchase all of the outstanding shares of CDK for $54.87 per share in cash in a tender offer. The agreement has been approved by the CDK board.

Our investigation concerns whether CDK’s board acted in the best interests of CDK shareholders in approving the sale to Brookfield, including whether the acquisition price adequately compensates CDK shareholders, and whether all material information regarding the transaction has been fully disclosed.

In particular, according to an analysis of Wall Street CDK price targets in the last 90 days published on Seeking Alpha, CDK has an average target price of $56.83 per share, and a high target price of $65.00 per share, both of which are above the price that Brookfield has agreed to pay.

Contact Us About This Case

"*" indicates required fields

If you lost money, enter $ amount, and hit "tab" to verify. If you have a gain, enter $0.
Please check box*
Hidden
This field is for validation purposes and should be left unchanged.
Click to Contact Us About This Case

Attorney

Joshua Fruchter
845-290-6818
alerts@wohlfruchter.com

  • Legal
  • Privacy Policy
  • Sitemap
  • Contact

Attorney Advertising. Prior results do not guarantee a similar outcome.

© 2023 Wohl & Fruchter LLP